Q4FY21 Result Update - Divi's Laboratories - ICICI Direct

Q4 revenues grew 28.7% YoY to Rs. 1788 crore (I-direct estimate: Rs. 1743 crore). Generic segment grew 24.8% YoY to Rs. 917 crore. Custom synthesis grew 25.5% YoY to Rs. 715 crore. Carotenoids grew 83.5% YoY to Rs. 156 crore. EBITDA margins expanded 807 bps YoY to 40.1% (I-direct estimates: 39.0%) due to better gross margin performance (up 458 bps YoY to 67.5%) and lower other expenditure. EBITDA grew 61.2% YoY to Rs. 716 crore (I-direct estimate: Rs. 680 crore). PAT grew 29.3% YoY to Rs. 502 crore (I-direct estimate: Rs. 472 crore) in-line with strong operational performance.

For details, click on the link below: Link to the report

Shares of DIVI'S LABORATORIES LTD. was last trading in BSE at Rs.4193.6 as compared to the previous close of Rs. 4116.5. The total number of shares traded during the day was 106927 in over 11120 trades.

The stock hit an intraday high of Rs. 4284.05 and intraday low of 4114. The net turnover during the day was Rs. 449204942.

Source : Equity Bulls

Keywords